Remove tag emerging-markets
article thumbnail

Electronic smart packaging market to value nearly $3b in 2033

European Pharmaceutical Review

A market report has identified that global demand for electronic smart packaging will reach $2.6 A largely addressable market means that there is continued interest in smart packaging worldwide. Yet apart from radio-frequency identification (RFID) tags and QR codes, adoption at scale has proved challenging overall, the report stated.

article thumbnail

RFID: The future of smart labelling?

Pharmaceutical Technology

The pharmaceutical industry began using radio frequency identification (RFID) tags in the early 2000s. Pfizer was the first to use the tech, adding RFID tags to track a Viagra (sildenafil) shipment circa 2006. Twenty years ago, the cost of implementing RFID tags and the ecosystem (software) was much more expensive than today.

Labelling 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Covid cash cow – a look at the Covid vaccine sales figures

pharmaphorum

The race to find and bring vaccines to market to fight Covid was impressive. Pfizer/BioNTech’s vaccine dominates the market. Together, these mRNA jabs have an iron grip on the covid vaccine market – in the US, they have consolidated a 90% market share. So too are the sales figures. Katrina Megget reports.

Vaccines 135
article thumbnail

Spatial Genomics, Transcriptomics and Proteomics Solutions – An Amelioration of Tissue Analytics

Roots Analysis

Furthermore, several live cell imaging and non-destructive fluorescence histological methods measure limited number of biomarkers at a time and the tags introduced may interfere with the natural function of genes and proteins. Likely Growth of the Spatial Omics Solutions Market.

52
article thumbnail

Biogen updates on its confirmatory Aduhelm trial

pharmaphorum

Aduhelm (aducanumab) was approved by the FDA in June, but has been held back by a glacial rollout as clinicians have questioned the data on which the decision to clear the drug was based, plus a $56,000 per year price tag, which has in turn led to pushback by payers.

FDA 52
article thumbnail

Risk sharing agreements soar as market access risk increases

Pharmaceutical Technology

These agreements have been particularly propelled by the recent rise in inflationary pressures and pharmaceutical market instability, pushing healthcare systems to find new ways to reduce risks associated with new drugs. Thus, a higher risk score reflects a more hostile market access environment and drug launch in a geographical area.

article thumbnail

Apellis set to take on Alexion as FDA clears PNH drug Empaveli

pharmaphorum

At the moment there’s no word on Apellis’ pricing plans, although that may emerge on an analysts’ call later today. PNH is an autoimmune disease characterised by uncontrolled activation of the complement system that results in the destruction of red blood cells and low levels of oxygen-carrying haemoglobin.

FDA 52